<DOC>
	<DOCNO>NCT01222624</DOCNO>
	<brief_summary>This prospective , open label , dose escalating , multicenter , phase I study measure safety , tolerability , pharmakokinetics PankoMab-GEX™ intravenous administration patient locally advance metastatic solid cancer refractory standard treatment . The effect PankoMab-GEX™ development antibody tumor response also evaluate .</brief_summary>
	<brief_title>PankoMab-GEX™ : Dose Escalation Study</brief_title>
	<detailed_description />
	<criteria>1 . Male female age ≥ 18 yr 2 . Histologicallyconfirmed TAMUC1 positive measurable nonmeasurable solid tumor accord RECIST criterion fail standard therapy standard therapy available ( TAMUC1 positivity assess PankoMabGEX™ stain immunohistology tumor ) . 3 . Failure standard therapy nonavailabilty standard therapy Patients must receive least 1 standard chemotherapy course tumor disease All therapies must complete 6 week ( therapeutic monoclonal antibody ) 4 week ( anticancer agent ) start study treatment patient must recover prior therapy toxicity least CTCAE grade 1 4 . Performance status : Eastern Cooperative Oncology Group ( ECOG ) 01 estimate life expectancy &gt; 3 month 5 . Adequate organ function assess follow laboratory parameter within 14 day prior study drug application : Bone marrow function : hemoglobin ≥ 100 g/L ; white blood cell count ( WBC ) ≥ 3.0 x 10^9/L ; absolute neutrophil count ( ANC ) ≥ 1.5x 10^9/L ; platelet count ≥ 100 x 10^9/L Hepatic : aspartate aminotransferase ( ASAT ) alanine aminotransferase ( ALAT ) ≤ 2.5 time upper limit normal ( ULN ) ( ≤ 5 x ULN hepatic metastasis present ) ; bilirubin ≤ 1.5 x ULN ; alkaline phosphatase ≤ 5.0 time upper limit normal ( ULN ) Renal : Calculated creatinine clearance &gt; 80 ml/min use MDRD formula accord Levey 2005 : Glomerular filtration rate ( GFR ) ( ml/min/1.73 m² ) = 186 x ( serum creatinine /0,95 ) ^1.154 x ( age ) ^0.203 x ( 0.742 female ) x ( 1.21 black patient ) 6 . Patients gender procreative potential must use effective contraception enrol study least 6 week last study drug infusion 7 . Written informed consent must obtain prior conduct studyspecific procedure 1 . Antibodybased immunotherapy within 6 week chemotherapy , radiation anticancer therapy within 4 week prior study enrolment 2 . Any investigational agent study enrolment 3 . Concurrent antitumor therapy concurrent immunotherapy 4 . Concurrent systemic steroid except topical ( inhaled , topical , nasal ) , replacement therapy last 28 day . Steroids low stable dose ( 20 mg prednisone ) give chronic disease also permit 5 . History allergic reaction previous antibody therapy 6 . Major surgery within 4 week prior enter study and/or incomplete recovery surgery plan major surgery 7 . Documented history active autoimmune disorder require systemic immunosuppressive therapy sarcoidosis , lupus erythematosus , rheumatoid arthritis , glomerulonephritis systemic vasculitis ( except autoimmune thyroiditis thyroid hormone replacement stable disease &gt; 1 year ) 8 . Primary secondary immune deficiency 9 . Clinically active infection &gt; CTCAE grade 2 10 . Prior allergic reaction monoclonal antibody ( e.g . Trastuzumab , Cetuximab Bevazizumab ) . 11 . Active hepatitis B C ; human immunodeficiency virus ( HIV ) seropositivity 12 . Any concurrent malignancy basal cell carcinoma carcinoma situ cervix . Patients previous malignancy without evidence disease ≥ 3 year allow enter study . 13 . Uncontrolled medical condition consider high risk treatment investigational drug include unstable diabetes mellitus , venacavasyndrome , chronic symptomatic respiratory disease . 14 . Brain metastasis leptomeningeal involvement 15 . Symptomatic congestive heart failure ( New York Heart Association [ NYHA ] 3 4 ) ; unstable angina pectoris within 6 month prior enrollment ; significant cardiac arrhythmia , history stroke transient ischemic attack within 1 year leave ventricular ejection fraction ( LVEF ) institutional range normal baseline multiple gated acquisition ( MUGA ) scan echocardiogram ( ECHO ) 16 . History seizure , encephalitis multiple sclerosis 17 . History deep vein thrombosis and/or thromboembolic event within past 6 month enter study and/or require anticoagulation therapy 18 . Evidence history bleed diathesis coagulopathy 19 . Active drug abuse chronic alcoholism 20 . Pregnancy Breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>advanced solid malignancy</keyword>
</DOC>